MORA Cure: MORA Cure (ETH-01K), developed by EverEx, Inc., is a digital therapeutics (S/W medical device) designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.
Treatment as Usual: In the control group, education is delivered and self-exercise is recommended.
Study summary
This randomized controlled confirmatory study will be evaluating an mobile application, MORA Cure (ETH-01K), owned by EverEx, Inc., to examine safety and effectiveness in individuals with patellofemoral pain syndrome.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Patients with peripatellar or posterior patellar pain in one or more knee joints for 3 months or longer
2. Patients with peripatellar or posterior patellar pain provoked by squatting
3. Patients who have pain provoked by 2 or more following activities: prolonged sitting, cycling, running, going up or down stairs, kneeling, compression of the patella, palpation of the patellar facets
4. Patients who signed a written informed consent form
Exclusion Criteria:
1. Patients with osteoarthritis which scored 3 or higher grade of the Kellgren-Lawrence scale
2. Patients diagnosed with a fracture or dislocation around the knee within the last 3 months
3. Patients who had knee surgery within the last 3 months
4. Patients diagnosed with patellar tendinitis based on imaging within 3 months
5. Patients taking narcotic pain medications for pain control
6. Patients taking or planning to take any medication that is a contraindication within the next 16 weeks at the time of screening
7. Patients who are pregnant
8. Patients currently participating in another clinical trial or have participated in another clinical trial within the past 3 months at the time of screening
9. Patients deemed unsuitable for this study by the investigator
Primary outcome measure(s)
Usual pain severity assessed by the Visual Analogue Scale (VAS) — 8 weeks Differences in usual pain severity between groups after the intervention. VAS score will be measured from 0 (no pain) to 100 (worst pain imaginable).
Trial sites (10)
Facility
City
Region
Status
Myongji Hospital
Goyang-si
Gyeonggi-do
Hanyang University Guri Hospital
Guri-si
Gyeonggi-do
Seoul National University Bundang Hospital
Gyeonggi-do
Gyeonggi-do
CHA Bundang Medical Center
Seongnam-si
Gyeonggi-do
Inha University Hospital
Junggu
Incheon
Chung-Ang University Hospital
Dongjak
Seoul
Seoul Metropolitan Government-Seoul National University Boramae Medical Center
Dongjak
Seoul
Kyung Hee University Hospital at Gangdong
Gangdong
Seoul
The Catholic University of Korea Seoul St. Mary's Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.